Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 12/20 | 0.53 |
| ▸ | FLT1 | P17948 | 3/20 | 0.44 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | ACP1 | P24666 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL787681 | 0.87 | KDR (0.51) | KDRFLT1PDE5APDGFRBKIT | |
| SCHEMBL3759288 | 0.78 | KDR (0.63) | KDREPAS1 | |
| SCHEMBL12475376 | 0.77 | KDR (0.57) | KDR | |
| SCHEMBL787842 | 0.77 | KDR (0.65) | KDR | |
| SCHEMBL3764417 | 0.72 | SHMT2 (0.60) | KDRFLT1PDGFRBKIT | |
| SCHEMBL4826429 | 0.71 | TSHR (0.68) | KDRACP1 | |
| SCHEMBL7913328 | 0.71 | KDR (0.69) | KDR | |
| Hydrochloric Acid SCHEMBL3976391 | 0.71 | LMNA (0.68) | ACP1 | |
| SCHEMBL657647 | 0.70 | HDAC3 (0.48) | HDAC3HDAC1HDAC2HDAC6SRC | |
| SCHEMBL10338919 | 0.70 | GOT1 (0.61) | KDRFLT1EPAS1PDE5APDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616443-A1 | PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS | Exelixis, Inc. (US) | 2013-07-24 | — | — | EP | disclosed |
| US-20130165440-A1 | JAK1 Inhibitors | EXELIXIS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| WO-2012037132-A1 | PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS | EXELIXIS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165440-A1 | JAK1 Inhibitors | JAK1, JAK2, JAK3 | KDR 1782/4885FLT1 696/4885EPAS1 1509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.